drugset

drugset / Trial / NCT01910610

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

NCT01910610 ↗

Phase 3 Unknown 464 enrolled GERCOR - Multidisciplinary Oncology Cooperative Group Hoffmann-La Roche · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.

Timeline

Start: 2013-10-30
Primary completion: 2023-07-13
Completion: 2024-12

Publications

Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M, Andre T, de Gramont A. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015 Jul 4;15:496. doi: 10.1186/s12885-015-1503-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	—	—
Subject	Cetuximab	Monoclonal antibody	—	—
Subject	Irinotecan	Small molecule	—	—
Subject	Panitumumab	Monoclonal antibody	—	—

Indications